Stonepine Capital Management
Latest statistics and disclosures from Stonepine Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ADMA, ALIM, EOLS, GLPG, RVNC, and represent 70.83% of Stonepine Capital Management's stock portfolio.
- Added to shares of these 10 stocks: ANIK, Rigel Pharmaceuticals, OPTN, GLPG, ACRS, RVNC, AUPH, Kiora Pharmaceuticals, SRZN, KZR.
- Started 12 new stock positions in ACAD, APRE, IRWD, TSVT, ACRS, AUPH, Kiora Pharmaceuticals, ETON, OPTN, SRZN. Rigel Pharmaceuticals, KZR.
- Reduced shares in these 10 stocks: ADMA (-$17M), EOLS (-$11M), NKTR, ALIM, CALC, RIGL, XERS, RZLT, MIST, TELA.
- Sold out of its positions in CALC, IOBT, NKTR, RZLT, RIGL, SCYX, XERS.
- Stonepine Capital Management was a net seller of stock by $-21M.
- Stonepine Capital Management has $110M in assets under management (AUM), dropping by -13.05%.
- Central Index Key (CIK): 0001440771
Tip: Access up to 7 years of quarterly data
Positions held by Stonepine Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Stonepine Capital Management
Stonepine Capital Management holds 25 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Adma Biologics (ADMA) | 19.1 | $21M | -45% | 1.9M | 11.18 |
|
| Alimera Sciences Com New (ALIM) | 17.8 | $20M | -13% | 3.5M | 5.56 |
|
| Evolus (EOLS) | 16.4 | $18M | -38% | 1.7M | 10.85 |
|
| Galapagos Nv- Spons Adr (GLPG) | 11.0 | $12M | +23% | 485k | 24.78 |
|
| Revance Therapeutics (RVNC) | 6.6 | $7.2M | +41% | 2.8M | 2.57 |
|
| Xoma Corp Com New (XOMA) | 5.4 | $5.9M | 250k | 23.69 |
|
|
| Anika Therapeutics (ANIK) | 3.8 | $4.2M | +171% | 165k | 25.33 |
|
| Tela Bio (TELA) | 2.7 | $2.9M | -9% | 626k | 4.70 |
|
| Rigel Pharmaceuticals Com New | 2.3 | $2.5M | NEW | 305k | 8.22 |
|
| Optinose (OPTN) | 2.2 | $2.4M | NEW | 2.4M | 1.04 |
|
| Aclaris Therapeutics (ACRS) | 1.9 | $2.1M | NEW | 1.9M | 1.10 |
|
| Scpharmaceuticals (SCPH) | 1.7 | $1.8M | -5% | 422k | 4.35 |
|
| Aurinia Pharmaceuticals (AUPH) | 1.6 | $1.7M | NEW | 300k | 5.71 |
|
| Milestone Pharmaceuticals (MIST) | 1.5 | $1.6M | -15% | 1.2M | 1.32 |
|
| Aytu Biopharma (AYTU) | 1.3 | $1.4M | 473k | 2.92 |
|
|
| Kiora Pharmaceuticals Com New | 0.8 | $840k | NEW | 200k | 4.20 |
|
| Adicet Bio (ACET) | 0.7 | $737k | +330% | 609k | 1.21 |
|
| Surrozen Com New (SRZN) | 0.7 | $724k | NEW | 66k | 10.95 |
|
| Exagen (XGN) | 0.6 | $653k | -6% | 359k | 1.82 |
|
| Kezar Life Sciences (KZR) | 0.6 | $630k | NEW | 1.1M | 0.60 |
|
| Aprea Therapeutics Com New (APRE) | 0.5 | $558k | NEW | 137k | 4.07 |
|
| 2seventy Bio (TSVT) | 0.4 | $385k | NEW | 100k | 3.85 |
|
| Eton Pharmaceuticals (ETON) | 0.3 | $362k | NEW | 110k | 3.29 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.3 | $313k | NEW | 48k | 6.52 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.1 | $81k | NEW | 5.0k | 16.25 |
|
Past Filings by Stonepine Capital Management
SEC 13F filings are viewable for Stonepine Capital Management going back to 2015
- Stonepine Capital Management 2024 Q2 restated filed Aug. 21, 2024
- Stonepine Capital Management 2024 Q2 filed Aug. 13, 2024
- Stonepine Capital Management 2024 Q1 filed May 15, 2024
- Stonepine Capital Management 2023 Q4 filed Feb. 13, 2024
- Stonepine Capital Management 2023 Q3 filed Nov. 13, 2023
- Stonepine Capital Management 2023 Q2 amended filed Aug. 16, 2023
- Stonepine Capital Management 2023 Q2 filed Aug. 11, 2023
- Stonepine Capital Management 2023 Q1 filed May 12, 2023
- Stonepine Capital Management 2022 Q4 filed Feb. 14, 2023
- Stonepine Capital Management 2022 Q3 filed Nov. 10, 2022
- Stonepine Capital Management 2022 Q2 filed Aug. 12, 2022
- Stonepine Capital Management 2022 Q1 filed May 16, 2022
- Stonepine Capital Management 2021 Q4 filed Feb. 14, 2022
- Stonepine Capital Management 2021 Q3 filed Nov. 12, 2021
- Stonepine Capital Management 2021 Q2 restated filed Aug. 16, 2021
- Stonepine Capital Management 2021 Q2 filed Aug. 13, 2021